Local Effect of Intranasal Beclomethasone Dipropionate Aerosol in Hay Fever

Mygind, Niels

doi:10.1136/bmj.4.5890.464

Cited by 138 publications

(64 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We treated the nasal allergy in these cases with BDA, and the excellent results we obtained prompted us to embark on a clinical trial at the end of 1970. The results of nasal BDA therapy in seasonal allergic rhinitis (SAR) have already been reported (Brown & Storey, 1974;Mygind, 1973;Blair & Butler, 1976;Lofkvist & Svensson, 1975). We now report on the long-term administration of BDA in the treatment of 223 patients with PAR and 92 with SAR.…”

Section: Introductionmentioning

confidence: 97%

Beclomethasone dipropionate aerosol in treatment of perennial and seasonal rhinitis: a review of five years' experience.

Brown¹,

Storey²,

Jackson³

1977

Brit J Clinical Pharma

View full text Add to dashboard Cite

1. Five years' experience in the use of beclomethasone dipropionate aerosol (BDA) in the treatment of 315 patients with upper respiratory tract allergy is reviewed. 2. A total of 223 patients with perennial rhinitis was treated. In 23, where the nasal allergy had recurred after oral corticosteroid therapy for asthma was withdrawn, BDA was effective in 69% of cases. A similar success rate (68%) was recorded in 169 patients suffering from perennial allergic rhinitis alone, but a satisfactory response was observed in only 45% of 31 patients with nasal polypi. 3. In 92 patients with seasonal allergic rhinitis freedom from symptoms was achieved in 80%. 4. A total of approximately 534 patient‐years of treatment has been recorded without any evidence of side‐effects either clinically or on nasal biopsy.

show abstract

Section: Introductionmentioning

confidence: 97%

Beclomethasone dipropionate aerosol in treatment of perennial and seasonal rhinitis: a review of five years' experience.

Brown¹,

Storey²,

Jackson³

1977

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…In 1973, Mygind [20] introduced beclomethasone dipropionate as a nasal spray for seasonal allergic rhinitis. Subsequently, several new topical corticosteroids have been developed: budesonide, flunisolide, fluocortinbutyl, fluticasone propionate, mometasone furoate, and triamcinolone acetonide (their commercial availability varies by country).…”

Section: Local Corticosteroidsmentioning

confidence: 99%

Evidence-based treatment of allergic rhinitis

Pawankar

Fokkens

2001

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Allergic rhinitis is an extremely common disease worldwide, affecting 10% to 50% of the population. An increasing prevalence of allergic rhinitis over the past decades and its frequent association with asthma have raised concerns about treating the disease appropriately. New knowledge of the pathophysiologic mechanisms underlying allergic inflammation of the airways has resulted in the development of newer and better therapeutic strategies. This review focuses on evidence-based treatment of allergic rhinitis, highlighting the most recent international consensus and evidence-based guidelines on allergic rhinitis.

show abstract

“…But only in 1972, did Black et al succeed in synthesizing antihistamines selective for the different receptors [39,40]. Later, in 1974, beclomethasone dipropionate, became, the most important goal for the treatment of allergic rhinitis after that of antihistamines [41].…”

Section: From Subcutaneous Immunotherapy To Sublingual Immunotherapy:mentioning

confidence: 99%

Unmet Needs in Understanding Sublingual Immunotherapy to Grass Pollen

Lorenzo¹,

Leto-Barone²,

Piana³

et al. 2017

Immunotherapy - Myths, Reality, Ideas, Future

View full text Add to dashboard Cite

The lack of medication for allergy symptoms at the end of the last millennium has been the promoter of the idea of treating allergies as if you were treating an infectious disease, by vaccination prophylaxis. Two forms of AIT 1) subcutaneous immunotherapy (SCIT) and 2) sublingual immunotherapy (SLIT) are used in the world. Considerable interest has emerged in SLIT both scientifically and especially financially. SLIT is not a new treatment modality. First description dates back to 1900 when H. Curtis. It was relatively widely used until the late 1970's mainly in US by homeopathic therapists.A number of case series describing experience with the oral route were published during the 1920s and 1930s, but it seems to have been perceived not as efficacious nor as well tolerated as subcutaneous immunotherapy. The companies producing allergen immunotherapy have an alliance with important opinion leaders on both shores of the Atlantic.If SLIT did not work for 40 years, why should it work for respiratory allergic diseases today? This question is the mother of all questions in the field of respiratory allergic diseases. The purpose of this chapter is to provide past and current information about immunotherapy, and discuss controversies over efficacy and safety, and dosing considerations for SLIT to grass.

show abstract

Local Effect of Intranasal Beclomethasone Dipropionate Aerosol in Hay Fever

Cited by 138 publications

References 11 publications

Beclomethasone dipropionate aerosol in treatment of perennial and seasonal rhinitis: a review of five years' experience.

Beclomethasone dipropionate aerosol in treatment of perennial and seasonal rhinitis: a review of five years' experience.

Evidence-based treatment of allergic rhinitis

Unmet Needs in Understanding Sublingual Immunotherapy to Grass Pollen

Contact Info

Product

Resources

About